The Sol Goldman Pancreatic Cancer Research Center

Pancreatic Cancer Early Detection for High Risk Individuals


Pancreatic Cancer Early Detection Screening Program


Our Research

The Pancreatic Cancer Early Detection Lab at the Sol Goldman Pancreatic Cancer Research center focuses on the primary goal of discovering the next breakthroughs in pancreatic cancer early detection. This lab puts together many techniques with a focus on genetics and evaluating the effectiveness of emerging detection methods including the utility of biomarkers in diagnosing early pancreatic cancer. We study both the genes that increase pancreatic cancer risk and the genetic changes that take place in pancreas tumors and precancerous lesions. Our team looks at different aspects of changes in pancreatic cancer, such as the methylation of certain genes and the activity of enzymes like telomerase that are involved in the development of tumors to understand what genetic signatures or proteins could be used to identify early pancreatic cancer.


Participating in the CAPS Research Study

The Cancer of the Pancreas Screening Study (CAPS) was developed to evaluate the effectiveness of early detection screening in high risk individuals of pancreatic cancer, and to progress the discovery of new biomarkers to improve early detection. Dr. Michael Goggins is the principal investigator for this study and Dr. Marcia Canto is the co- primary investigator and lead clinician for the study. Drs. Goggins and Canto are widely recognized as authorities in the field of pancreatic cancer screening, and have been working together to evaluate the utility of pancreatic screening for approximately 15 years. Currently, Drs. Goggins and Canto lead the CAPS5 research study. CAPS5 is evaluating pancreas screening with endoscopic ultrasound, the potential diagnostic use of fluid analysis for early detection of pancreatic cancer, the use of secretin to collect pancreas juice for fluid analysis and discovery of gene mutations linked to the development of pancreatic cancer.

CAPS enrolls a wide cohort of individuals with higher risk of pancreatic cancer, including those with genetic predispositions and patients who are undergoing EUS for other reasons. We collect bio-specimens, including small amounts of blood and pancreas juice, in order to profile changes in proteins, RNA and DNA and understand the potential use of fluid analysis in pancreatic cancer diagnoses. To collect pancreas juice, the study team ask for optional consent to receive secretin, an FDA- approved drug that is a synthetic version of a hormone stimulating the pancreas to produce juice. Our research team can help you understand more about participating in our research if you are interested.

The lead study coordinator and research nurse, Hilary Cosby (R.N., C.G.R.N.) assists with scheduling of pancreas screening including gastroenterology consultation, scheduling of EUS, MRI, CT and incorporating optional genetic counseling into your visits.

To answer questions or schedule participation in the CAPS Research Study please contact Hilary Cosby at 410-502-2893.